Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
about
Mechanically produced schistosomula as a higher-throughput tools for phenotypic pre-screening in drug sensitivity assays: current research and future trendsEvaluation of an FDA approved library against laboratory models of human intestinal nematode infectionsFluorescence/luminescence-based markers for the assessment of Schistosoma mansoni schistosomula drug assays.Defining the Schistosoma haematobium kinome enables the prediction of essential kinases as anti-schistosome drug targets.Revisiting the SAR of the Antischistosomal Aryl Hydantoin (Ro 13-3978).Controlling schistosomiasis with praziquantel: How much longer without a viable alternative?Mechanisms of action and therapeutic efficacies of the lipophilic antimycobacterial agents clofazimine and bedaquiline.Discovery of New Anti-Schistosomal Hits by Integration of QSAR-Based Virtual Screening and High Content Screening.Nobel prize for the artemisinin and ivermectin discoveries: a great boost towards elimination of the global infectious diseases of poverty.Sertraline, Paroxetine, and Chlorpromazine Are Rapidly Acting Anthelmintic Drugs Capable of Clinical Repurposing.Antischistosomal agents: state of art and perspectives.Progress in antischistosomal N,N'-diaryl urea SAR.Schistosomiasis therapeutics: whats in the pipeline?Screening a repurposing library, the Medicines for Malaria Venture Stasis Box, against Schistosoma mansoni.Immunohistochemical Investigations of Treatment with Ro 13-3978, Praziquantel, Oxamniquine, and Mefloquine in Schistosoma mansoni-Infected Mice.The antidepressant drug paroxetine as a new lead candidate in schistosome drug discovery
P2860
Q28071848-16628EBE-0B4E-49A9-9E08-BF946906A30DQ28383181-E8925EAA-5FF2-42A2-8E9C-6F82B01E8F3DQ35862985-42EEC233-CD75-463B-989D-C6DA00573FDCQ36346161-8B47DDCC-DA09-414A-9E5B-70582723D5C6Q37493746-FF1F65AF-B814-45B3-8E99-02FAC9EC283CQ37726920-02023401-A838-42C4-B3BF-144907EC9941Q38995175-CCA0190E-4ABF-4F0B-87B7-ED632EF88234Q39300204-C96AB376-7471-4B19-A8EB-F2A87769C506Q43115498-028C165E-7AC5-4CD2-B105-6422E9A091A4Q47653287-7D552020-012E-4F8B-8BA0-CCAD8ACB2E30Q47784982-5D6DF8CA-4A2C-465D-8881-93CE3F372541Q50114403-3320372A-9A5A-4581-8F11-750361FFE8E9Q50966400-7C8ECBB2-09A5-438D-99EE-CFC091B36A03Q55008133-3E4F7F54-C5A0-4AE5-8C4E-CB02AAA9F3B7Q55112826-9E4AD0BA-F0D9-445F-A248-CB8D520BCAFDQ56514272-45533118-2C40-4C2B-ADDA-85106B332F6B
P2860
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
description
2015 nî lūn-bûn
@nan
2015 թուականին հրատարակուած գիտական յօդուած
@hyw
2015 թվականին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@ast
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@en
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@nl
type
label
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@ast
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@en
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@nl
prefLabel
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@ast
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@en
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@nl
P2860
P50
P3181
P1476
Activity Profile of an FDA-Approved Compound Library against Schistosoma mansoni
@en
P2093
Ivan Scandale
P2860
P304
P3181
P356
10.1371/JOURNAL.PNTD.0003962
P407
P577
2015-01-01T00:00:00Z